BMO Capital Lowers Scholar Rock Holding's Price Target to $45.00, Maintains "Outperform" Rating

BMO Capital has revised its price target for Scholar Rock Holding (SRRK) to $45.00 from $57.00, maintaining its "Outperform" rating. The decrease in price target reflects a 21.05% drop. Analyst Etzer Darout conducted the analysis. The company's pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The average one-year price target from 7 analysts is $50.57, with an upside of 46.10% from the current price.

BMO Capital has revised its price target for Scholar Rock Holding (SRRK) to $45.00 from $57.00, maintaining its "Outperform" rating. The decrease in price target reflects a 21.05% drop, as per an analysis conducted by analyst Etzer Darout. The company's pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The average one-year price target from 7 analysts is $50.57, with an upside of 46.10% from the current price [2].

The price target reduction comes as BMO Capital cited ongoing problems at Novo’s Catalent (NYSE:CTLT) facilities that could potentially impact the PDUFA date for apitegromab, Scholar Rock’s investigational drug. Apitegromab is produced within Novo’s Catalent facilities, which were previously flagged for FDA observations during a pre-approval site visit, creating uncertainty around the drug’s regulatory timeline. Last week, Regeneron (NASDAQ:REGN) received a Complete Response Letter (CRL) for odronextamab approval and experienced a delayed response for the label extension of Eylea HD Q4W dosing, suggesting broader regulatory challenges related to Novo Catalent facilities [2].

Scholar Rock reported its second-quarter 2025 earnings, which showed an EPS of -0.98. This result was below the expected EPS of -0.66, representing a 48.48% negative surprise. The earnings miss has raised concerns among investors regarding the company’s financial performance. Additionally, Raymond James has maintained its Strong Buy rating for Scholar Rock, with a price target of $53.00. These developments highlight key areas of interest for investors monitoring Scholar Rock’s progress [2].

References:
[1] https://www.marketbeat.com/instant-alerts/filing-15942-shares-in-scholar-rock-holding-corporation-nasdaqsrrk-bought-by-universal-beteiligungs-und-servicegesellschaft-mbh-2025-08-03/
[2] https://www.investing.com/news/analyst-ratings/bmo-capital-lowers-scholar-rock-stock-price-target-to-45-on-novo-catalent-concerns-93CH-4176986